Noncirrhotic hepatocellular carcinoma: Derivation from hepatocellular adenoma¿ Clinicopathologic analysis

Modern Pathology

Volumn 27, Issue 3, 2014, Pages 420-432

  Liu, Ta Chiang ^a   Vachharajani, Neeta ^a   Chapman, William C ^a   Brunt, Elizabeth M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

catenin; Cirrhosis; Glutamine synthetase; Liver fatty acid binding protein; Metabolic syndrome; Serum amyloid A

Indexed keywords

BETA CATENIN; CYTOKERATIN 19; FATTY ACID BINDING PROTEIN; GLUTAMATE AMMONIA LIGASE; GLYPICAN 3; LIVER FATTY ACID BINDING PROTEIN; PROTEIN P53; SERUM AMYLOID A; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HEPATITIS C; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER ADENOMA; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MORPHOLOGICAL TRAIT; OBESITY; PRIORITY JOURNAL; SEX RATIO; TUMOR DIFFERENTIATION; TUMOR VOLUME; VERY ELDERLY; YOUNG ADULT;

ADENOMA, LIVER CELL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; COMORBIDITY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84896728059     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.148     Document Type: Article

References (40)

1. Bruix J, Llovet JM. Two decades of advances in hepatocellular carcinoma research. Semin Liver Dis 2010;30: 1-2.
2. Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010;51: 1972-1978.
3. Paradis V, Zalinski S, Chelbi E, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009;49: 851-859.
4. Sanyal A, Poklepovic A, Moyneur E, et al. Populationbased risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin 2010;26: 2183-2191.
5. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362: 1907-1917.
6. Brancatelli G, Federle MP, Grazioli L, et al. Hepatocellular carcinoma in noncirrhotic liver: CT, clinical, and pathologic findings in 39 U.S. residents. Radiology 2002;222: 89-94.
7. Trevisani F, Frigerio M, Santi V, et al. Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig Liver Dis 2010;42: 341-347.
8. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53: 1020-1022.
9. Sherman M. Hepatocellular carcinoma: screening and staging. Clin Liver Dis 2011;15: 323-334.
10. Bioulac-Sage P, Balabaud C, Zucman-Rossi J. Subtype classification of hepatocellular adenoma. Dig Surg 2010;27: 39-45.
11. Zucman-Rossi J, Jeannot E, Nhieu JT, et al. Genotypephenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006;43: 515-524.
12. Bioulac-Sage P, Cubel G, Balabaud C, et al. Revisiting the pathology of resected benign hepatocellular nodules using new immunohistochemical markers. Semin Liver Dis 2011;31: 91-103.
13. Bioulac-Sage P, Rebouissou S, Thomas C, et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 2007;46: 740-748.
14. Evason KJ, Grenert JP, Ferrell LD, et al. Atypical hepatocellular adenoma-like neoplasms with betacatenin activation show cytogenetic alterations similar to well-differentiated hepatocellular carcinomas. Hum Pathol 2013;44: 750-758.
15. Paradis V, Benzekri A, Dargere D, et al. Telangiectatic focal nodular hyperplasia: a variant of hepatocellular adenoma. Gastroenterology 2004;126: 1323-1329.
16. Rebouissou S, Amessou M, Couchy G, et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 2009;457: 200-204.
17. Pilati C, Amessou M, Bihl MP, et al. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med 2011;208: 1359-1366.
18. Laurent C, Blanc JF, Nobili S, et al. Prognostic factors and longterm survival after hepatic resection for hepatocellular carcinoma originating from noncirrhotic liver. J Am Coll Surg 2005;201: 656-662.
19. Theise ND, Curado MP, Franceschi S, et al. Hepatocellular Carcinoma. IARC: Lyon, 2010.
20. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991;13: 372-374.
21. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41: 1313-1321.
22. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Panel. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285: 2486-2497.
23. Di Tommaso L, Franchi G, Park YN, et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 2007;45: 725-734.
24. Yamauchi N, Watanabe A, Hishinuma M, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 2005;18: 1591-1598.
25. Shafizadeh N, Ferrell LD, Kakar S. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol 2008;21: 1011-1018.
26. Coston WM, Loera S, Lau SK, et al. Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry. Am J Surg Pathol 2008;32: 433-444.
27. Villanueva A, Hoshida Y. Depicting the role of TP53 in hepatocellular carcinoma progression. J Hepatol 2011; 55: 724-725.
28. Uenishi T, Kubo S, Yamamoto T, et al. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci 2003;94: 851-857.
29. Durnez A, Verslype C, Nevens F, et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 2006;49: 138-151.
30. Yang XR, Xu Y, Shi GM, et al. Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection. Clin Cancer Res 2008;14: 3850-3859.
31. Dupont-Bierre E, Compagnon P, Raoul JL, et al. Resection of hepatocellular carcinoma in noncirrhotic liver: analysis of risk factors for survival. J Am Coll Surg 2005;201: 663-670.
32. Stoot JH, Coelen RJ, De Jong MC, et al. Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. HPB (Oxford) 2010; 12: 509-522.
33. Farges O, Dokmak S. Malignant transformation of liver adenoma: an analysis of the literature. Dig Surg 2010; 27: 32-38.
34. Farges O, Ferreira N, Dokmak S, et al. Changing trends in malignant transformation of hepatocellular adenoma. Gut 2011;60: 85-89.
35. Micchelli ST, Vivekanandan P, Boitnott JK, et al. Malignant transformation of hepatic adenomas. Mod Pathol 2008;21: 491-497.
36. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010;51: 1820-1832.
37. National health and nutrition examination survey 2005- 2006. Accessed at http://www.cdc.gov/nchs/products/ pubs/pubd/hestats/overweight/overweight-adult. pdf. 2009.
38. Balkau B, Vernay M, Mhamdi L, et al. The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French D.E.S.I.R. study. Diabetes Metab 2003;29: 526-532.
39. Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 2009;115: 5651-5661.
40. Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin Liver Dis 2007;11:191-207; (x-xi).